Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages

Robin Bruyndonckx1*, Niel Hens1,2, Marc Aerts3, Herman Goossens3, Geert Molenberghs1,4 and Samuel Coenen3,5

1Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), University of Hasselt, Diepenbeek, Belgium; 2Centre for Health Economic Research and Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium; 3Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium; 4Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Catholic University of Leuven, Leuven, Belgium; 5Centre for General Practice, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

*Corresponding author. Tel: +32-11-268246; Fax: +32-11-268299; E-mail: robin.bruyndonckx@uhasselt.be

Received 1 October 2013; returned 21 January 2014; revised 4 February 2014; accepted 17 February 2014

Objectives: To complement analyses of the linear trend and seasonal fluctuation of European outpatient antibiotic use expressed in defined daily doses (DDD) by analyses of data in packages, to assess the agreement between both measures and to study changes in the number of DDD per package over time.

Methods: Data on outpatient antibiotic use, aggregated at the level of the active substance (WHO version 2011) were collected from 2000 to 2007 for 31 countries and expressed in DDD and packages per 1000 inhabitants per day (DID and PID, respectively). Data expressed in DID and PID were analysed separately using non-linear mixed models while the agreement between these measurements was analysed through a joint non-linear mixed model. The change in DDD per package over time was studied with a linear mixed model.

Results: Total outpatient antibiotic and penicillin use in Europe and their seasonal fluctuation significantly increased in DID, but not in PID. The use of combinations of penicillins significantly increased in DID and in PID. Broad-spectrum penicillin use did not increase significantly in DID and decreased significantly in PID. For all but one subgroup, country-specific deviations moved in the same direction whether measured in DID or PID. The correlations are not perfect. The DDD per package increased significantly over time for all but one subgroup.

Conclusions: Outpatient antibiotic use in Europe shows contrasting trends, depending on whether DID or PID is used as the measure. The increase of the DDD per package corroborates the recommendation to adopt PID to monitor outpatient antibiotic use in Europe.

Keywords: antibiotic consumption, ambulatory care, dose change, non-linear mixed model

Introduction

A link between antibiotic use and antimicrobial resistance has been demonstrated both in ecological studies and in randomized controlled trials in individual patients.1–4 Resistance is a major public health problem because it is related to treatment failure, prolonged hospitalization, increased costs of care and increased mortality.4 One part of the solution is to gather trustworthy information on the consumption of antibiotics.4

In Europe, the European Surveillance of Antimicrobial Consumption (ESAC) project—currently ESAC-Net, coordinated by the European Centre for Disease Prevention and Control (ECDC; www.ecdc.europa.eu/en/activities/surveillance/ESAC-Net)—consists of a network of surveillance systems that enables the collection of data on European antibiotic consumption. The ESAC project revealed that total outpatient antibiotic use expressed in the number of defined daily doses (DDD) per 1000 inhabitants per day (DID) increased significantly over time (between 1997 and 2009), while showing a significant seasonal fluctuation with a high winter peak, which decreased over time.5 More detailed analyses of major antibiotic subgroups have been described in separate papers.7–12

The ESAC project group also proposed an additional outcome measure, i.e. the number of packages per 1000 inhabitants per day (PID), because expressing outpatient antibiotic use in DID is not always optimal.6 This is the case when the number of DDD per package (or prescription or treatment or person) differs substantially between the elements of a comparison, e.g. when comparing between different countries or within a country over time. More recently, a comparison of different measures showed that...
Because measurements were taken quarterly for each country, the data are correlated and hence mixed-effects models are an adequate tool to study the trends in the data. Mixed-effects models describe outcomes for individual countries from this average trend.\textsuperscript{13,14} The seasonal fluctuation in the data can be modelled using a non-linear mixed model.\textsuperscript{15,16} As a starting model, the non-linear mixed model previously applied in the analysis of the ESAC data was used.\textsuperscript{17} In this model, the intercept reflects the antibiotic consumption at baseline (first quarter of 2000) and the slope reflects the change in antibiotic consumption over time (per quarter); the amplitude for the sine function is split into two parts, with a time-independent part reflecting the amplitude of the upward winter and downward summer peak and a time-dependent part reflecting the change of the amplitude over time. From this starting model the final model was obtained by means of maximum likelihood. A more elaborate description of this procedure and the motivation for the use of maximum likelihood rather than restricted maximum likelihood can be found in the Technical Notes (available as Supplementary data at JAC Online). The overall fit of the model was evaluated by plotting the observed and predicted values over time for all countries. To present a clear illustrative figure, the fit was plotted for the European average as well as for two neighbouring member states with contrasting outpatient antibiotic use (Belgium and the Netherlands).

### Results

A detailed description of the results for the group of antibacterials for systemic use (J01) will be given. Results for other major antibiotic subgroups will be shown in tables, but their full description can be consulted elsewhere.\textsuperscript{18}

### Analysis of DID and PID separately

#### Analysis of DID

Antibacterial consumption ranged from 3.24 to 48.06 DID. In DID there was a significant increase in total antibiotic consumption over time in Europe, with a significant seasonal fluctuation that increased significantly over time (Table 1). The model seemed to fit the data well, given that both the average and country-specific lines approximated the observed data (Figure 1). Furthermore, the longitudinal analysis showed a high positive correlation between the volume of use and the seasonal fluctuation (see the Technical Notes). This means that, in terms of absolute amounts in DID, high-consumption countries at baseline tended to have higher seasonal fluctuation and vice versa.

#### Analysis of PID

Antibacterial consumption varied from 1.024 to 9.899 PID. In PID there was a non-significant decrease in total antibiotic consumption in Europe over time, with a significant seasonal fluctuation that did not significantly change over time (Table 1). The model appears to fit the data well (Figure 2). Also in the PID model, the longitudinal analysis showed a high positive correlation between the volume of use and the seasonal fluctuation (see the Technical Notes), meaning that in terms of absolute amounts in PID, high-consumption countries at baseline tended to have higher seasonal fluctuation and vice versa. Parameter estimates in DID and PID separately are also shown in Table 1 for the major antibiotic subgroups. Both in DID and in PID, the use and seasonal fluctuation of combinations of
penicillins (J01CR) and quinolones (J01M) increased in Europe, and that of tetracyclines (J01A) and trimethoprim (J01E) decreased significantly over time. Penicillin (J01C) use and seasonal fluctuation significantly increased in DID and not in PID. Broad-spectrum penicillin (J01CA) use did not increase significantly in DID and decreased significantly in PID, as did its seasonal fluctuation. For cephalosporins (J01D), no significant changes over time were observed. For all but one subgroup (J01X) the seasonal fluctuation with an upward winter peak was significant whether expressing the consumption in DID or PID.

Table 1. Estimated linear trend and seasonal variation in outpatient antibiotic use in Europe expressed in DID and PID based on available quarterly data for 2000–07

<table>
<thead>
<tr>
<th>ATC classification</th>
<th>DID</th>
<th>PID</th>
</tr>
</thead>
<tbody>
<tr>
<td>J01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J01C</td>
<td>14.2404**</td>
<td>3.1006**</td>
</tr>
<tr>
<td>J01CA</td>
<td>5.9694**</td>
<td>1.3529**</td>
</tr>
<tr>
<td>J01CR</td>
<td>3.6967**</td>
<td>0.6533**</td>
</tr>
<tr>
<td>J01F</td>
<td>2.0284**</td>
<td>0.3486**</td>
</tr>
<tr>
<td>J01M</td>
<td>1.8342**</td>
<td>0.4543**</td>
</tr>
<tr>
<td>J01D</td>
<td>1.1847**</td>
<td>0.2012**</td>
</tr>
<tr>
<td>J01E</td>
<td>1.8794**</td>
<td>0.5268**</td>
</tr>
<tr>
<td>J01X</td>
<td>1.8911**</td>
<td>0.2371**</td>
</tr>
<tr>
<td>J01BGR</td>
<td>0.9900**</td>
<td>0.1876**</td>
</tr>
<tr>
<td>J01A</td>
<td>0.0357</td>
<td>0.0187**</td>
</tr>
<tr>
<td>J01E</td>
<td>0.0117**</td>
<td>0.1302**</td>
</tr>
</tbody>
</table>

\[\beta_0\] (fixed intercept), predicted average outpatient use in the first quarter of 2000; \[\beta_1\] (fixed slope), predicted average increase (if positive)/decrease (if negative) in use per quarter; \[\beta_2\] (fixed seasonal variation), predicted average amplitude of the upward winter and downward summer peak in use; \[\beta_3\] (fixed damping effect), predicted average increase (if positive)/decrease (if negative) of the amplitude of the upward winter and downward summer peak in use per quarter.

*P < 0.05.
**P < 0.0001.
A joint model was constructed based on the final models for DID and PID. The estimated correlations between matching random effects in DID and PID were 0.77 (95% CI: 0.63, 0.92; between random intercepts), 0.86 (95% CI: 0.75, 0.97; between random slopes) and 0.96 (95% CI: 0.89, 1.02; between random amplitudes; Figure 3). All correlations were high and positive, indicating that there is an agreement in the random effects. This means that when the random term in DID is above average it will generally be above average in PID as well, and vice versa. Only the correlation between the random amplitudes seemed perfect.

For the major antibiotic subgroups the same procedure was followed, which also resulted in a joint model for DID and PID and correlations between matching random effects. Both the correlation between random intercepts in DID and PID and the correlation between random slopes in DID and PID were positive for all subgroups, but none seemed perfect. The correlation between the amplitudes in DID and PID was positive for all but one subgroup (other antibiotics, concatenation of J01B, J01G and J01R). It seemed perfect for combinations of penicillins [0.90 (95% CI: 0.95, 1.03)], macrolides [0.99 (95% CI: 0.97, 1.02)] and the subgroup of other antibiotics [concatenation of J01B, J01G and J01R; −0.67 (95% CI: −1.20, −0.13)].

**Figure 3.** Correlation between matching random effects from the joint model of total outpatient antibiotic use in DID and PID: intercepts (top left), slopes (top right) and amplitudes (bottom). Note: that the intercepts combination for CH is close to UK, for NO it is close to NL, for AT to DE, and for HU to PL; that the slopes combination for HR is close to BE, for EE, HU and PT it is close to CZ, for FI to SI, for SK to IT, for NL, CH, DE, SE, NO and AT to RU, and for LU to ES; and that the amplitudes combination for NO is close to NL, for RU it is close to DK, for DE, CH and FI to UK, for PT and ES to BE, and for SK and LU to PL. These countries are omitted from the figures for clarity. Random intercept: predicted country-specific antibiotic use at baseline (first quarter of 2000). Slope: predicted country-specific change in antibiotic use over time. Amplitude: predicted country-specific amplitude of the upward winter peaks and downward summer troughs in antibiotic use. AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; IL, Israel; IT, Italy; LT, Lithuania; LU, Luxembourg; LV, Latvia; NL, Netherlands; NO, Norway; PL, Poland; PT, Portugal; RO, Romania; RU, Russian Federation; SE, Sweden; SI, Slovenia; SK, Slovakia; TR, Turkey; UK, United Kingdom.
Outpatient antibiotic use in Europe (2000–07)

Table 2. Estimated linear trend in the number of DDD per package for outpatient antibiotic use in Europe based on available quarterly data for 2000–07

<table>
<thead>
<tr>
<th>ATC classification</th>
<th>β₀</th>
<th>β₁</th>
</tr>
</thead>
<tbody>
<tr>
<td>J01</td>
<td>4.9149 (0.2891)**</td>
<td>0.0436 (0.0059)**</td>
</tr>
<tr>
<td>J01C</td>
<td>4.8265 (0.3798)**</td>
<td>0.0617 (0.0087)**</td>
</tr>
<tr>
<td>J01CA</td>
<td>6.6670 (0.4998)**</td>
<td>0.0573 (0.0106)**</td>
</tr>
<tr>
<td>J01CR</td>
<td>5.8891 (0.3731)**</td>
<td>0.0693 (0.0099)**</td>
</tr>
<tr>
<td>J01F</td>
<td>4.9924 (0.3571)**</td>
<td>0.0390 (0.0079)**</td>
</tr>
<tr>
<td>J01M</td>
<td>6.1181 (0.2671)**</td>
<td>0.0105 (0.0075)</td>
</tr>
<tr>
<td>J01D</td>
<td>3.9906 (0.3487)**</td>
<td>0.0428 (0.0115)*</td>
</tr>
<tr>
<td>J01A</td>
<td>9.2237 (0.9723)**</td>
<td>0.0433 (0.0146)*</td>
</tr>
<tr>
<td>J01E</td>
<td>5.2627 (0.2154)**</td>
<td>0.0083 (0.0034)*</td>
</tr>
<tr>
<td>J01X</td>
<td>1.0179 (0.2254)**</td>
<td>0.0086 (0.0037)*</td>
</tr>
<tr>
<td>J01BGR</td>
<td>1.1447 (0.3420)**</td>
<td>0.0778 (0.0367)*</td>
</tr>
</tbody>
</table>

J01, antibacterials for systemic use; J01C, penicillins; J01CA, penicillins with extended spectrum; J01CR, combinations of penicillins; J01F, macrolides; J01M, quinolones; J01D, cephalosporins; J01A, tetracyclines; J01E, sulphonamides; J01X, urinary antiseptics; J01BGR, other antibiotics (concatenation of amphenicols (J01B), aminoglycosides (J01G) and combinations of antibacterials (J01R)).

Analysis of the change in DDD per package

Parameter estimates for the fixed effects (Europe) are given in Table 2. The average DDD per package in 2000 varied between 1 and 9. There was an increase in DDD per package over time, with the size of the quarterly increase ranging between 0.01 and 0.08 DDD. This translates to a yearly increase of 0.04–0.31 DDD per package. This increase was significant for total antibiotic consumption and consumption of all subgroups, strong correlations between the random intercepts were found. The correlations did not seem perfect, however, implying that when the average antibiotic consumption expressed in DID and PID is known, country-specific information on either measure is not sufficient to obtain information on the other measure. In addition, this study also found strong correlations between the random changes over time in DID and PID and between the random amplitudes in DID and PID, only the latter seeming perfect for total antibiotic consumption and consumption of combinations of penicillins, macrolides and other antibiotics. To our knowledge, this is the first longitudinal data analysis of outpatient antibiotic use data in PID. Moreover, we were able to complement analyses of DID data with analyses of PID data from the same source, i.e. IMS Health. The results of the separate DID analyses are comparable to those of the ESAC data, cross-validating both data sources. This is also the first account of the evolution of DID per package for outpatient antibiotic use in Europe.

Except for the quinolones, the DID per package increased significantly over time. As DID per package can change over time, so can the number of packages per treatment in some countries. Therefore, improved fit of pack sizes to treatment regimens might partly explain trends in PID. However, analysis of Belgian national data, also showing increasing DID per package,6 has revealed that this impact is limited and does not alter the conclusion that outpatient antibiotic use in Belgium has been decreasing.13

As suggested by ESAC and already adopted by ESAC-Net, ECDC continues collecting both DID and PID data for the surveillance of outpatient antibiotic use in Europe.20 The results of the longitudinal data analyses presented here, e.g. the contrasting trends for Europe and Belgium in DID and PID, respectively, confirm the relevance of adopting packages as an additional outcome to better understand linear trends and seasonal fluctuations in outpatient antibiotic use in Europe, especially in the case of increasing DID per package and when assessing interventions to reduce antibiotic prescribing.

To study the change in antibiotic consumption over time, it is recommended to collect information on both DID and PID or to be cautious when interpreting results based on DID alone.

Further study could investigate whether the description of outpatient antibiotic use can be improved by including change points in the model, e.g. to assess the impact of the European Antibiotic Awareness Day,21,22 and what outcome measure correlates best with antimicrobial resistance.

Conclusions

Outpatient antibiotic use in Europe shows contrasting trends depending on whether the internationally accepted DID is used or PID, which is considered a good proxy for treatments. The increase of the DID per package corroborates the recommendation to adopt PID to survey outpatient antibiotic use in Europe.

Acknowledgements

We would like to thank Peter Stephens of IMS Health for providing the data and Arno Müller for data management. Support from the Methusalem financing programme of the Flemish Government and the IAP Research Network P7/06 of the Belgian State (Belgian Science Policy) is gratefully acknowledged. N. H. acknowledges support from the University of Antwerp scientific chair in Evidence-Based Vaccinology, financed in 2009–13 by a gift from Pfizer.
Funding
ESAC was funded by the European Centre for Disease Prevention and Control (ECDC; Grant Agreement 2007/001).

Transparency declarations
None to declare.

Supplementary data
The Technical Notes are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org).

References